Healio (7/9, Gramigna) reported, “Vortioxetine more effectively improved depression, anxiety and cognition than placebo,” investigators concluded after conducting “a meta-analysis of studies of vortioxetine (Trintellix, Takeda/Lundbeck) among adults with major depressive disorder [MDD],” including “17 randomized, double-blind, placebo-controlled clinical trials that compared oral vortioxetine monotherapy with placebo as acute MDD treatment.” The findings were published online June 15 in the Journal of Clinical Psychiatry. (SOURCE: APA Headlines)